Trials / Completed
CompletedNCT06345066
A Study of LY3841136 in Overweight and Obese Participants
A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC. |
| DRUG | LY3841136 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2024-04-03
- Primary completion
- 2025-09-29
- Completion
- 2025-09-29
- First posted
- 2024-04-03
- Last updated
- 2025-10-15
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06345066. Inclusion in this directory is not an endorsement.